<p>你可能會認為，<strong>Lifecore Biomedical, Inc.</strong>（納斯達克代碼：LFCR）以 2.4 倍的市銷率（&#34;P/S&#34;）值得關注，因為幾乎一半的美國生命科學公司市銷率超過 3.7 倍，甚至超過 7 倍的市銷率也並不罕見。然而，我們需要深入挖掘一下，以確定這種較低的市銷率是否有合理的依據。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現的各個方面進行研發。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>查看我們對 Lifecore Biomedical 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811"/></p>
<p>納斯達克 GS:LFCR 市銷率與行業比較 2026 年 1 月 20 日</p>
<h3>Lifecore Biomedical 最近的表現如何？</h3>
<p>最近，Lifecore Biomedical 的表現並不理想，因為其收入增長速度低於大多數其他公司。似乎許多人預計這種乏善可陳的收入表現將持續下去，這抑制了市銷率的增長。如果是這樣的話，現有股東可能會對股價未來的走勢感到失望。</p>
<p>如果你想了解分析師對未來的預測，可以查看我們關於 Lifecore Biomedical 的 <strong>免費</strong> 報告。</p>
<h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
<p>為了證明其市銷率的合理性，Lifecore Biomedical 需要產生低迷的增長，且增長速度落後於行業。</p>
<p>回顧過去，我們看到該公司在過去一年幾乎沒有可言的收入增長。儘管如此，得益於早期的增長，收入在三年前的基礎上總共提升了 16%。因此，我們認為該公司在收入增長方面的表現是喜憂參半的。</p>
<p>展望未來，根據跟蹤該公司的四位分析師的預測，收入預計在未來三年內每年增長 5.8%。而行業預計每年將實現 6.5% 的增長，因此該公司的收入表現與行業相當。</p>
<p>根據這些信息，我們覺得奇怪的是，Lifecore Biomedical 的市銷率低於行業水平。可能大多數投資者並不相信該公司能夠實現未來的增長預期。</p>
<h2>最後的總結</h2>
<p>一般來説，我們傾向於將市銷率的使用限制在評估市場對公司整體健康狀況的看法上。</p>
<p>我們看到，Lifecore Biomedical 目前的市銷率低於預期，因為其預測增長與更廣泛的行業一致。低市銷率可能表明市場對收入增長預期的質疑。然而，如果你同意分析師的預測，你可能能夠以有吸引力的價格買入該股票。</p>
<p>在你形成觀點之前，我們發現了 <strong>Lifecore Biomedical 的 2 個警示信號</strong>，你應該注意。</p>
<p>重要的是要 <strong>確保你尋找的是一家優秀的公司，而不僅僅是你遇到的第一個想法。</strong> 因此，如果持續盈利能力符合你對優秀公司的定義，可以查看這個 <strong>免費</strong> 的有趣公司名單，這些公司最近的盈利增長強勁且市盈率較低。</p>

LFCR

<p>Lifecore Biomedical, Inc.（納斯達克代碼：LFCR）的市銷率為 2.4 倍，低於行業平均水平 3.7 倍，顯示出潛在的投資機會。儘管在三年內收入增長了 16%，但近期增長乏力，預計年增長率為 5.8%，而行業平均為 6.5%。較低的市銷率表明市場對公司未來增長的懷疑。如果投資者與分析師的預測一致，可能會發現價值，但由於已識別的警示信號，建議保持謹慎</p>

<p>You may think that with a price-to-sales (or &#34;P/S&#34;) ratio of 2.4x <strong>Lifecore Biomedical, Inc.</strong> (NASDAQ:LFCR) is a stock worth checking out, seeing as almost half of all the Life Sciences companies in the United States have P/S ratios greater than 3.7x and even P/S higher than 7x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>你可能會認為，<strong>Lifecore Biomedical, Inc.</strong>（納斯達克代碼：LFCR）以 2.4 倍的市銷率（&#34;P/S&#34;）值得關注，因為幾乎一半的美國生命科學公司市銷率超過 3.7 倍，甚至超過 7 倍的市銷率也並不罕見。然而，我們需要深入挖掘一下，以確定這種較低的市銷率是否有合理的依據。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現的各個方面進行研發。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>Check out our latest analysis for Lifecore Biomedical</p>
<div class="lb-trans"><p>查看我們對 Lifecore Biomedical 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811" alt="" original-src="https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811"/></p>
<p>NasdaqGS:LFCR Price to Sales Ratio vs Industry January 20th 2026</p>
<div class="lb-trans"><p>納斯達克 GS:LFCR 市銷率與行業比較 2026 年 1 月 20 日</p>
</div><h3>How Has Lifecore Biomedical Performed Recently?</h3>
<div class="lb-trans"><h3>Lifecore Biomedical 最近的表現如何？</h3>
</div><p>Recent times haven't been great for Lifecore Biomedical as its revenue has been rising slower than most other companies. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.</p>
<div class="lb-trans"><p>最近，Lifecore Biomedical 的表現並不理想，因為其收入增長速度低於大多數其他公司。似乎許多人預計這種乏善可陳的收入表現將持續下去，這抑制了市銷率的增長。如果是這樣的話，現有股東可能會對股價未來的走勢感到失望。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Lifecore Biomedical.</p>
<div class="lb-trans"><p>如果你想了解分析師對未來的預測，可以查看我們關於 Lifecore Biomedical 的 <strong>免費</strong> 報告。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
</div><p>In order to justify its P/S ratio, Lifecore Biomedical would need to produce sluggish growth that's trailing the industry.</p>
<div class="lb-trans"><p>為了證明其市銷率的合理性，Lifecore Biomedical 需要產生低迷的增長，且增長速度落後於行業。</p>
</div><p>Taking a look back first, we see that there was hardly any revenue growth to speak of for the company over the past year. Regardless, revenue has managed to lift by a handy 16% in aggregate from three years ago, thanks to the earlier period of growth. So it appears to us that the company has had a mixed result in terms of growing revenue over that time.</p>
<div class="lb-trans"><p>回顧過去，我們看到該公司在過去一年幾乎沒有可言的收入增長。儘管如此，得益於早期的增長，收入在三年前的基礎上總共提升了 16%。因此，我們認為該公司在收入增長方面的表現是喜憂參半的。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 5.8% per annum during the coming three years according to the four analysts following the company. With the industry predicted to deliver 6.5% growth each year, the company is positioned for a comparable revenue result.</p>
<div class="lb-trans"><p>展望未來，根據跟蹤該公司的四位分析師的預測，收入預計在未來三年內每年增長 5.8%。而行業預計每年將實現 6.5% 的增長，因此該公司的收入表現與行業相當。</p>
</div><p>With this information, we find it odd that Lifecore Biomedical is trading at a P/S lower than the industry. It may be that most investors are not convinced the company can achieve future growth expectations.</p>
<div class="lb-trans"><p>根據這些信息，我們覺得奇怪的是，Lifecore Biomedical 的市銷率低於行業水平。可能大多數投資者並不相信該公司能夠實現未來的增長預期。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最後的總結</h2>
</div><p>Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>一般來説，我們傾向於將市銷率的使用限制在評估市場對公司整體健康狀況的看法上。</p>
</div><p>We've seen that Lifecore Biomedical currently trades on a lower than expected P/S since its forecast growth is in line with the wider industry. The low P/S could be an indication that the revenue growth estimates are being questioned by the market. However, if you agree with the analysts' forecasts, you may be able to pick up the stock at an attractive price.</p>
<div class="lb-trans"><p>我們看到，Lifecore Biomedical 目前的市銷率低於預期，因為其預測增長與更廣泛的行業一致。低市銷率可能表明市場對收入增長預期的質疑。然而，如果你同意分析師的預測，你可能能夠以有吸引力的價格買入該股票。</p>
</div><p>Before you settle on your opinion, we've discovered <strong>2 warning signs for Lifecore Biomedical</strong> that you should be aware of.</p>
<div class="lb-trans"><p>在你形成觀點之前，我們發現了 <strong>Lifecore Biomedical 的 2 個警示信號</strong>，你應該注意。</p>
</div><p>It's important to <strong>make sure you look for a great company, not just the first idea you come across.</strong> So if growing profitability aligns with your idea of a great company, take a peek at this <strong>free</strong> list of interesting companies with strong recent earnings growth (and a low P/E).</p>
<div class="lb-trans"><p>重要的是要 <strong>確保你尋找的是一家優秀的公司，而不僅僅是你遇到的第一個想法。</strong> 因此，如果持續盈利能力符合你對優秀公司的定義，可以查看這個 <strong>免費</strong> 的有趣公司名單，這些公司最近的盈利增長強勁且市盈率較低。</p>
</div>

Lifecore Biomedical, Inc.（納斯達克股票代碼：LFCR）的低市銷率可能意味着一個投資機會